Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided response generally matches the supplied FDA label excerpted risks (serious infections, increased mortality, malignancy, MACE, thrombosis), with correct label section citations (5.1–5.5). However, it does not actually verify that these are the boxed warning elements specifically (it cites Warnings and Precautions sections rather than the boxed warning text), so boxed-warning correspondence is not fully auditable from the supplied information.
Category Scores
Accurate Statements
Increased risk of mortality may occur with XELJANZ/XELJANZ XR.
Supported by Label section 5.2 Increased Risk of Mortality.
Malignancies and lymphoproliferative disorders may occur with XELJANZ/XELJANZ XR.
Supported by Label section 5.3 Malignancy and Lymphoproliferative Disorders.
Major adverse cardiovascular events (MACE) may occur with XELJANZ/XELJANZ XR.
Supported by Label section 5.4 Major Adverse Cardiovascular Events.
Thrombosis may occur with XELJANZ/XELJANZ XR (including PE/DVT and arterial thrombosis).
Supported by Label section 5.5 Thrombosis.
Serious and sometimes fatal infections may occur with XELJANZ/XELJANZ XR.
Supported by Label section 5.1 Serious Infections.
Unsupported Statements
Boxed warning elements (serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis) are supported by the FDA label for XELJANZ/XELJANZ XR.
The response provides citations to Warnings and Precautions sections (5.1–5.5) but does not provide/quote the actual BOXED WARNING text or confirm that these items correspond exactly to the boxed warning content.
The FDA label content is contained in Warnings and Precautions (5.1–5.5) as excerpted above.
This asserts boxed-warning correspondence to sections 5.1–5.5; the supplied excerpt does not show boxed-warning labeling or boxed-warning text.
Contradictions
Important Omissions
Actual boxed warning text (or explicit boxed-warning section reference such as the label's 'BOXED WARNING' block) demonstrating that these five items are exactly the boxed warning elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response correctly identifies risks that are present in the provided label excerpts (5.1–5.5). The only gap is that it does not verify these correspond specifically to the boxed warning text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Boxed-warning correspondence is not auditable: the response cites Warnings and Precautions (5.1–5.5) rather than providing the actual boxed warning block text or explicit boxed warning reference.
Suggested Improvement
Quote or explicitly cite the FDA label BOXED WARNING block and show that its listed elements are exactly serious infections, increased mortality, malignancy, MACE, and thrombosis.